EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Leveraging Mobile Health to Improve Capecitabine Adherence Among Women With Breast Cancer: A Pilot Randomized Controlled Trial

Ilana Graetz iD, Samuel Hernandez, Sara Arshad, Kristina Byers iD, Jane Meisel, Gelareh Sadigh iD, Elizabeth A Sakach, Keerthi Gogineni iD, Mylin A Torres iD

JCO Oncology Practice · 25.06.2024

DOI: 10.1200/op.24.00031 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift JCO Oncology Practice, online erschienen am 25.06.2024. Verfasst von Ilana Graetz und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Policy and Management, Emory Rollins School of Public Health, Atlanta, GA. Hauptthemen laut MEDLINE: Breast Neoplasms, Capecitabine, Medication Adherence, Telemedicine. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Oral capecitabine improves convenience compared to intravenous therapies but presents monitoring challenges. We conducted a randomized pilot trial to evaluate a mobile health intervention to remotely monitor capecitabine adherence and patient-reported outcomes (PROs) among women with breast cancer. METHODS Patients with breast cancer prescribed capecitabine, an oral chemotherapy with a complex, cyclical regimen, were randomly assigned to enhanced usual care (EUC) or PRO arm. Participants were asked to use a smart pill bottle to measure adherence (timing and dose) and complete baseline and 90-day follow-up surveys. PRO participants received text messages for missed or incorrect doses and weekly text-based symptom assessments, and their oncologists received alerts for severe symptoms or missed doses. We compared nonadherence (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsCapecitabineMedication AdherenceTelemedicineHumansFemalePilot ProjectsMiddle AgedAdultAntimetabolites, AntineoplasticAgedQuality of LifeText Messaging

Substanzen

CapecitabineAntimetabolites, Antineoplastic

Autor:innen und Institutionen

  • Department of Health Policy and Management, Emory Rollins School of Public Health, Atlanta, GA.
  • Novartis Pharmaceutical Corporation, Atlanta, GA.
  • Department of Hematology and Oncology, Winship Cancer Institute, Emory University, Atlanta, GA.
  • Department of Radiological Sciences, University of California Irvine, Orange, CA.
  • Department of Radiation Oncology, Winship Cancer Institute, Emory University, Atlanta, GA.

ORCID-Profile: Ilana Graetz, Kristina Byers, Gelareh Sadigh, Keerthi Gogineni, Mylin A Torres

Förderung

  • NCI NIH HHS

Zitieren

APA

Graetz, I., Hernandez, S., Arshad, S., Byers, K., Meisel, J., Sadigh, G., Sakach, E. A., Gogineni, K., & Torres, M. A. (2024). Leveraging Mobile Health to Improve Capecitabine Adherence Among Women With Breast Cancer: A Pilot Randomized Controlled Trial. JCO Oncology Practice. https://doi.org/10.1200/op.24.00031

Vancouver

Graetz I, Hernandez S, Arshad S, Byers K, Meisel J, Sadigh G, et al. Leveraging Mobile Health to Improve Capecitabine Adherence Among Women With Breast Cancer: A Pilot Randomized Controlled Trial. JCO Oncology Practice. 2024. doi:10.1200/op.24.00031

BibTeX
@article{Graetz2024,
  author = {Graetz, Ilana and Hernandez, Samuel and Arshad, Sara and Byers, Kristina and Meisel, Jane and Sadigh, Gelareh and Sakach, Elizabeth A and Gogineni, Keerthi and Torres, Mylin A},
  title = {Leveraging Mobile Health to Improve Capecitabine Adherence Among Women With Breast Cancer: A Pilot Randomized Controlled Trial},
  journal = {JCO Oncology Practice},
  year = {2024},
  doi = {10.1200/op.24.00031}
}
Kostenlos starten →